These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 1891788

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.
    van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW.
    Blood; 1991 Jan 01; 77(1):201-5. PubMed ID: 1984797
    [Abstract] [Full Text] [Related]

  • 3. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy.
    Blundell EL, Pamphilon DH, Fraser ID, Menitove JE, Greenwalt TJ, Snyder EL, Repucci AJ, Hedberg SL, Anderson JK, Buchholz DH, Kagen LR, Aster RH.
    Transfusion; 1996 Apr 01; 36(4):296-302. PubMed ID: 8623127
    [Abstract] [Full Text] [Related]

  • 4. Leukocyte-depleted blood components prevent platelet refractoriness in patients with acute myeloid leukemia.
    Oksanen K.
    Eur J Haematol; 1994 Aug 01; 53(2):100-7. PubMed ID: 8088380
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Determination in vivo viability of a transfused platelet product by corrected count increment and percentage platelet response.
    Thuku NW, Shikuku K, Mbugua A.
    Pan Afr Med J; 2017 Aug 01; 27():226. PubMed ID: 28979628
    [Abstract] [Full Text] [Related]

  • 7. Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
    Sniecinski I, O'Donnell MR, Nowicki B, Hill LR.
    Blood; 1988 May 01; 71(5):1402-7. PubMed ID: 3282572
    [Abstract] [Full Text] [Related]

  • 8. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J, Bronfman L, Bertín P, Marzouka E, Hidalgo P, Amaya S, Mezzano D.
    Rev Med Chil; 1997 Nov 01; 125(11):1305-12. PubMed ID: 9609051
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization.
    Murphy MF, Metcalfe P, Thomas H, Eve J, Ord J, Lister TA, Waters AH.
    Br J Haematol; 1986 Mar 01; 62(3):529-34. PubMed ID: 3954967
    [Abstract] [Full Text] [Related]

  • 13. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia.
    Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP.
    Blood; 1983 Oct 01; 62(4):815-20. PubMed ID: 6349715
    [Abstract] [Full Text] [Related]

  • 14. Development of white blood cell fragments, during the preparation and storage of platelet concentrates, as measured by using real-time polymerase chain reaction.
    Dijkstra-Tiekstra MJ, van der Schoot CE, Pietersz RN, Huijgens PC, van der Meer PF, Reesink HW.
    Vox Sang; 2004 Nov 01; 87(4):250-6. PubMed ID: 15585020
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
    Hogge DE, McConnell M, Jacobson C, Sutherland HJ, Benny WB, Massing BG.
    Transfusion; 1995 Aug 01; 35(8):645-52. PubMed ID: 7631404
    [Abstract] [Full Text] [Related]

  • 17. Refractoriness to platelet transfusions in children with acute leukemia.
    DeCoteau J, Haddad S, Blanchette V, Poon A.
    J Pediatr Hematol Oncol; 1995 Nov 01; 17(4):306-10. PubMed ID: 7583385
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration.
    Andreu G, Dewailly J, Leberre C, Quarre MC, Bidet ML, Tardivel R, Devers L, Lam Y, Soreau E, Boccaccio C.
    Blood; 1988 Sep 01; 72(3):964-9. PubMed ID: 3416079
    [Abstract] [Full Text] [Related]

  • 20. Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components.
    Dzieczkowski JS, Barrett BB, Nester D, Campbell M, Cook J, Sugrue M, Andersen JW, Anderson KC.
    Transfusion; 1995 Jan 01; 35(1):20-5. PubMed ID: 7998063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.